Skip to main content

Advertisement

SpringerLink
Log in

Sentinel node biopsy for breast cancer: past, present, and future

  • Special Feature
  • Recent advances in sentinel node biopsy for breast cancer
  • Published:
Breast Cancer Aims and scope Submit manuscript

Abstract

Sentinel node biopsy has replaced axillary lymph node dissection as the standard of care in early breast cancers. Sentinel node biopsy represents a highly accurate and less-morbid axillary staging, which allows most patients to avoid unnecessary axillary lymph node dissection and its morbidity. This review provides information including several issues which are still under debate, such as clinical significance of micrometastases, avoidance of axillary lymph node dissection for patients with positive sentinel nodes, accuracy and timing of sentinel node biopsy in patients undergoing neoadjuvant chemotherapy, and how many sentinel nodes are sufficient for removal. Finally, a new topic is introduced: superparamagnetic iron oxide (SPIO)-enhanced magnetic resonance (MR) imaging for the detection of metastases in sentinel nodes localized by computed tomography (CT)-lymphography (CT-LG) in patients with breast cancer. SPIO-enhanced MR imaging is a useful method of detecting metastases in sentinel nodes localized by CT-LG in patients with breast cancer. Patients with clinically negative nodes may be spared even sentinel node biopsy when the sentinel node is diagnosed as disease free using SPIO-enhanced MR imaging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.

    Article  CAS  PubMed  Google Scholar 

  2. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–401.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15:2345–50.

    CAS  PubMed  Google Scholar 

  4. Krag DN, Weaver DL, Alex JC, Fairbank JT. Surgical resection and radiolocalization of the sentinel node in breast cancer using a gamma probe. Surg Oncol. 1993;2:335–9.

    Article  CAS  PubMed  Google Scholar 

  5. Motomura K, Inaji H, Komoike Y, Kasugai T, Nagumo S, Noguchi S, et al. Sentinel node biopsy in breast cancer patients with clinically negative lymph-nodes. Breast Cancer. 1999;6:259–62.

    Article  PubMed  Google Scholar 

  6. Motomura K, Inaji H, Komoike Y, Hasegawa Y, Kasugai T, Noguchi S, et al. Combination technique is superior to dye alone in identification of the sentinel node in breast cancer. J Surg Oncol. 2001;76:95–9.

    Article  CAS  PubMed  Google Scholar 

  7. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, et al. The sentinel node in breast cancer: a multicenter validation study. N Engl J Med. 1998;339:941–6.

    Article  CAS  PubMed  Google Scholar 

  8. Veronesi U, Paganelli G, Galimberti V, Viale G, Zurrida S, Bedoni M, et al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative lymph-nodes. Lancet. 1997;349:1864–7.

    Article  CAS  PubMed  Google Scholar 

  9. Albertini JJ, Lyman GH, Cox C, Yeatman T, Balducci L, Ku N, et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA. 1996;276:1818–22.

    Article  CAS  PubMed  Google Scholar 

  10. Cox CE, Pendas S, Cox JM, Joseph E, Shons AR, Yeatman T, et al. Guidelines for sentinel node biopsy and lymphatic mapping of patients with breast cancer. Ann Surg. 1998;227:645–53.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Tafra L, Lannin DR, Swanson MS, Van Eyk JJ, Verbanac KM, Chua AN, et al. Multicenter trial of sentinel node biopsy for breast cancer using both technetium sulfur colloid and isosulfan blue dye. Ann Surg. 2001;233:51–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Zervos EE, Burak WE Jr. Lymphatic mapping for breast cancer: experience at the Ohio State University. Breast Cancer. 2000;7:195–200.

    Article  CAS  PubMed  Google Scholar 

  13. McMasters KM, Tuttle TM, Carlson DJ, Brown CM, Noyes RD, Glaser RL, et al. Sentinel lymph node biopsy for breast cancer: a suitable alternative to routine axillary dissection in multi-institutional practice when optimal technique is used. J Clin Oncol. 2000;18:2560–6.

    CAS  PubMed  Google Scholar 

  14. Giuliano AE, Hawes D, Ballman KV, Whitworth PW, Blumencranz PW, Reintgen DS, et al. Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer. JAMA. 2011;306(4):385–93.

    Article  CAS  PubMed  Google Scholar 

  15. Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Ashikaga T, et al. National Surgical Adjuvant Breast and Bowel Project. Technical outcomes of sentinel-lymph-node resection and conventional axillary-lymph-node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomized phase III trial. Lancet Oncol. 2007;8(10):881–8.

    Article  CAS  PubMed  Google Scholar 

  16. Goyal A, Newcombe RG, Chhabra A. ALMANAC Trialists Group. Factors affecting failed localization and false-negative rates of sentinel node biopsy in breast cancer—results of the ALMANAC validation phase. Breast Cancer Res Treat. 2006;99(2):203–8.

    Article  PubMed  Google Scholar 

  17. Giuliano AE, Haigh PI, Brennan MB, Hansen NM, Kelley MC, Ye W, et al. Prospective observational study of sentinel lymphadenectomy without further axillary dissection in patients with sentinel node-negative breast cancer. J Clin Oncol. 2000;18(13):2553–9.

    CAS  PubMed  Google Scholar 

  18. Veronesi U, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V, et al. Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. Ann Surg. 2010;251(4):595–600.

    Article  PubMed  Google Scholar 

  19. Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240(3):462–8.

    Article  PubMed Central  PubMed  Google Scholar 

  20. Hunt KK, Ballman KV, McCall LM, Boughey JC, Mittendorf EA, Cox CE, et al. Factors associated with local-regional recurrence after a negative sentinel node dissection: results of the ACOSOG Z0010 trial. Ann Surg. 2012;256(3):428–36.

    Article  PubMed  Google Scholar 

  21. van der Ploeg IM, Nieweg OE, van Rijk MC, Valdés Olmos RA, Kroon BB. Axillary recurrence after a tumour-negative sentinel node biopsy in breast cancer patients: a systematic review and meta-analysis of the literature. Eur J Surg Oncol. 2008;34(12):1277–84.

    Article  PubMed  Google Scholar 

  22. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, et al. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet. 1999;354(9182):896–900.

    Article  CAS  PubMed  Google Scholar 

  23. Hainsworth PJ, Tjandra JJ, Stillwell RG, Machet D, Henderson MA, Rennie GC, et al. Detection and significance of occult metastases in node-negative breast cancer. Br J Surg. 1993;80(4):459–63.

    Article  CAS  PubMed  Google Scholar 

  24. Chen SL, Hoehne FM, Giuliano AE. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Surg Oncol. 2007;14(12):3378–84.

    Article  PubMed  Google Scholar 

  25. Giuliano AE, Dale PS, Turner RR, Morton DL, Evans SW, Krasne DL. Improved axillary staging of breast cancer with sentinel lymphadenectomy. Ann Surg. 1995;222(3):394–9.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  26. Dowlatshahi K, Fan M, Bloom KJ, Spitz DJ, Patel S, Snider HC Jr. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: a preliminary study. Cancer. 1999;86(6):990–6.

    Article  CAS  PubMed  Google Scholar 

  27. Motomura K, Komoike Y, Inaji H, Hasegawa Y, Kasugai T, Noguchi S, et al. Multiple sectioning and immunohistochemical staining of sentinel nodes in patients with breast cancer. Br J Surg. 2002;89(8):1032–4.

    Article  CAS  PubMed  Google Scholar 

  28. Weaver DL, Ashikaga T, Krag DN, Skelly JM, Anderson SJ, Harlow SP, et al. Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med. 2011;364(5):412–21.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  29. Lyman GH, Giuliano AE, Somerfield MR, Benson AB 3rd, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703–20.

    Article  PubMed  Google Scholar 

  30. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer v.1.2012. The National Comprehensive Cancer Network, Jenkintown. 2012. http://www.nccn.org. Accessed July 2012.

  31. Hansen NM, Grube B, Ye X, Turner RR, Brenner RJ, Sim MS, et al. Impact of micrometastases in the sentinel node of patients with invasive breast cancer. J Clin Oncol. 2009;27(28):4679–84.

    Article  PubMed  Google Scholar 

  32. de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, et al. Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med. 2009;361(7):653–63.

    Article  PubMed  Google Scholar 

  33. Guenther JM, Hansen NM, DiFronzo LA, Giuliano AE, Collins JC, Grube BL, et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg. 2003;138(1):52–6.

    Article  PubMed  Google Scholar 

  34. Naik AM, Fey J, Gemignani M, Heerdt A, Montgomery L, Petrek J, et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg. 2004;240(3):462–8.

    Article  PubMed Central  PubMed  Google Scholar 

  35. Swenson KK, Mahipal A, Nissen MJ, Tuttle TM, Heaton K, Lally RM, et al. Axillary disease recurrence after sentinel lymph node dissection for breast carcinoma. Cancer. 2005;104(9):1834–9.

    Article  PubMed  Google Scholar 

  36. Jeruss JS, Winchester DJ, Sener SF, Brinkmann EM, Bilimoria MM, Barrera E Jr, et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol. 2005;12(1):34–40.

    Article  PubMed  Google Scholar 

  37. Park J, Fey JV, Naik AM, Borgen PI, Van Zee KJ, Cody HS 3rd. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Ann Surg. 2007;245(3):462–8.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Hwang RF, Gonzalez-Angulo AM, Yi M, Buchholz TA, Meric-Bernstam F, Kuerer HM, et al. Low locoregional failure rates in selected breast cancer patients with tumor-positive sentinel lymph nodes who do not undergo completion axillary dissection. Cancer. 2007;110(4):723–30.

    Article  PubMed  Google Scholar 

  39. Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, et al. Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer. J Clin Oncol. 2009;27(18):2946–53.

    Article  PubMed  Google Scholar 

  40. Spiguel L, Yao K, Winchester DJ, Gorchow A, Du H, Sener SF, et al. Sentinel node biopsy alone for node-positive breast cancer: 12-year experience at a single institution. J Am Coll Surg. 2011;213(1):122–8.

    Article  PubMed  Google Scholar 

  41. Pepels MJ, de Boer M, Bult P, van Dijck JA, van Deurzen CH, Menke-Pluymers MB, et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells. Ann Surg. 2012;255(1):116–21.

    Article  PubMed  Google Scholar 

  42. Yi M, Giordano SH, Meric-Bernstam F, Mittendorf EA, Kuerer HM, Hwang RF, et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs. SLNB with axillary lymph node dissection for node-positive breast cancer patients: experience from the SEER database. Ann Surg Oncol. 2010;17(Suppl 3):343–51.

    Article  PubMed Central  PubMed  Google Scholar 

  43. Wasif N, Maggard MA, Ko CY, Giuliano AE. Underuse of axillary dissection for the management of sentinel node micrometastases in breast cancer. Arch Surg. 2010;145(2):161–6.

    Article  PubMed  Google Scholar 

  44. Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, et al. Update of International Breast Cancer Study Group Trial 23-01 to compare axillary dissection versus no axillary dissection in patients with clinically node negative breast cancer and micrometastases in the sentinel node. Cancer Res. 2012;71:S3–1.

    Google Scholar 

  45. Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. JAMA. 2011;305(6):569–75.

    Article  CAS  PubMed  Google Scholar 

  46. Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–32.

    PubMed  Google Scholar 

  47. Kaufmann M, von Minckwitz G, Mamounas EP, Cameron D, Carey LA, Cristofanilli M, et al. Recommendations from an international consensus conference on the current status and future of neoadjuvant systemic therapy in primary breast cancer. Ann Surg Oncol. 2012;19(5):1508–16.

    Article  PubMed  Google Scholar 

  48. Chung MH, Ye W, Giuliano AE. Role for sentinel lymph node dissection in the management of large (> or =5 cm) invasive breast cancer. Ann Surg Oncol. 2001;8(9):688–92.

    CAS  PubMed  Google Scholar 

  49. Bedrosian I, Reynolds C, Mick R, Callans LS, Grant CS, Donohue JH, et al. Accuracy of sentinel lymph node biopsy in patients with large primary breast tumors. Cancer. 2000;88(11):2540–5.

    Article  CAS  PubMed  Google Scholar 

  50. Ollila DW, Neuman HB, Sartor C, Carey LA, Klauber-Demore N. Lymphatic mapping and sentinel lymphadenectomy prior to neoadjuvant chemotherapy in patients with large breast cancers. Am J Surg. 2005;190(3):371–5.

    Article  PubMed  Google Scholar 

  51. Cox CE, Cox JM, White LB, Stowell NG, Clark JD, Allred N, et al. Sentinel node biopsy before neoadjuvant chemotherapy for determining axillary status and treatment prognosis in locally advanced breast cancer. Ann Surg Oncol. 2006;13(4):483–90.

    Article  PubMed  Google Scholar 

  52. Schrenk P, Tausch C, Wölfl S, Bogner S, Fridrik M, Wayand W. Sentinel node mapping performed before preoperative chemotherapy may avoid axillary dissection in breast cancer patients with negative or micrometastatic sentinel nodes. Am J Surg. 2008;196(2):176–83.

    Article  PubMed  Google Scholar 

  53. Grube BJ, Christy CJ, Black D, Martel M, Harris L, Weidhaas J, et al. Breast sentinel lymph node dissection before preoperative chemotherapy. Arch Surg. 2008;143(7):692–9.

    Article  PubMed  Google Scholar 

  54. Papa MZ, Zippel D, Kaufman B, Shimon-Paluch S, Yosepovich A, Oberman B, et al. Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer. J Surg Oncol. 2008;98(6):403–6.

    Article  PubMed  Google Scholar 

  55. Straver ME, Rutgers EJ, Russell NS, Oldenburg HS, Rodenhuis S, Wesseling J, et al. Towards rational axillary treatment in relation to neoadjuvant therapy in breast cancer. Eur J Cancer. 2009;45(13):2284–92.

    Article  CAS  PubMed  Google Scholar 

  56. Lang JE, Esserman LJ, Ewing CA, Rugo HS, Lane KT, Leong SP, et al. Accuracy of selective sentinel lymphadenectomy after neoadjuvant chemotherapy: effect of clinical node status at presentation. J Am Coll Surg. 2004;199(6):856–62.

    Article  PubMed  Google Scholar 

  57. Shimazu K, Tamaki Y, Taguchi T, Akazawa K, Inoue T, Noguchi S. Sentinel lymph node biopsy using periareolar injection of radiocolloid for patients with neoadjuvant chemotherapy-treated breast carcinoma. Cancer. 2004;100(12):2555–61.

    Article  PubMed  Google Scholar 

  58. Mamounas EP, Brown A, Anderson S, Smith R, Julian T, Miller B, et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2005;23(12):2694–702.

    Article  PubMed  Google Scholar 

  59. Xing Y, Foy M, Cox DD, Kuerer HM, Hunt KK, Cormier JN. Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer. Br J Surg. 2006;93(5):539–46.

    Article  CAS  PubMed  Google Scholar 

  60. Lee S, Kim EY, Kang SH, Kim SW, Kim SK, Kang KW, et al. Sentinel node identification rate, but not accuracy, is significantly decreased after pre-operative chemotherapy in axillary node-positive breast cancer patients. Breast Cancer Res Treat. 2007;102(3):238–88.

    Google Scholar 

  61. Kinoshita T. Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy. Breast Cancer. 2007;14(1):10–5.

    Article  PubMed  Google Scholar 

  62. Tausch C, Konstantiniuk P, Kugler F, Reitsamer R, Roka S, Pöstlberger S, et al. Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group. Ann Surg Oncol. 2008;15(12):3378–83.

    Article  PubMed  Google Scholar 

  63. Gimbergues P, Abrial C, Durando X, Le Bouedec G, Cachin F, Penault-Llorca F, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy is accurate in breast cancer patients with a clinically negative axillary nodal status at presentation. Ann Surg Oncol. 2008;15(5):1316–21.

    Article  CAS  PubMed  Google Scholar 

  64. Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study. J Clin Oncol. 2009;27(5):726–32.

    Article  PubMed  Google Scholar 

  65. Kelly AM, Dwamena B, Cronin P, Carlos RC. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy-systematic review and meta analysis. Acad Radiol. 2009;16(5):551–63.

    Article  PubMed  Google Scholar 

  66. Hunt KK, Yi M, Mittendorf EA, Guerrero C, Babiera GV, Bedrosian I, et al. Sentinel lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg. 2009;250(4):558–66.

    PubMed  Google Scholar 

  67. van Deurzen CH, Vriens BE, Tjan-Heijnen VC, van der Wall E, Albregts M, van Hilligersberg R, et al. Accuracy of sentinel node biopsy after neoadjuvant chemotherapy in breast cancer patients: a systematic review. Eur J Cancer. 2009;45(18):3124–30.

    Article  PubMed  Google Scholar 

  68. Wong SL, Edwards MJ, Chao C, Tuttle TM, Noyes RD, Carlson DJ, et al. Sentinel lymph node biopsy for breast cancer: impact of the number of sentinel nodes removed on the false-negative rate. J Am Coll Surg. 2001;192:684–9.

    Article  CAS  PubMed  Google Scholar 

  69. Martin RC, Fey J, Yeung H, Borgen PI, Cody HS 3rd. Highest isotope count does not predict sentinel node positivity in all breast cancer patients. Ann Surg Oncol. 2001;8:592–7.

    Article  CAS  PubMed  Google Scholar 

  70. Zervos EE, Badgwell BD, Abdessalam SF, Farrar WB, Walker MJ, Yee LD, et al. Selective analysis of the sentinel node in breast cancer. Am J Surg. 2001;182:372–6.

    Article  CAS  PubMed  Google Scholar 

  71. Zakaria S, Degnim AC, Kleer CG, Diehl KA, Cimmino VM, Chang AE, et al. Sentinel lymph node biopsy for breast cancer: how many nodes are enough? J Surg Oncol. 2007;96:554–9.

    Article  PubMed  Google Scholar 

  72. Tangoku A, Yamamoto S, Suga K, Ueda K, Nagashima Y, Hida M, et al. Sentinel lymph node biopsy using computed tomography-lymphography in patients with breast cancer. Surgery. 2004;135:258–65.

    Article  PubMed  Google Scholar 

  73. Motomura K, Ishitobi M, Komoike Y, Koyama H, Inaji H, Horinouchi T, et al. True sentinel nodes identified by CT-lymphography accurately stage the axilla in patients with breast cancer: removal of true sentinel nodes alone is sufficient. Cancer Res. 2011; 70:P1-01-30.

    Google Scholar 

  74. Harisinghani MG, Barentsz J, Hahn PF, Deserno WM, Tabatabaei S, van de Kaa CH, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491–9.

    Article  PubMed  Google Scholar 

  75. Motomura K, Ishitobi M, Komoike Y, Koyama H, Noguchi A, Sumino H, et al. SPIO-enhanced magnetic resonance imaging for the detection of metastases in sentinel nodes localized by computed tomography lymphography in patients with breast cancer. Ann Surg Oncol. 2011;18:3422–9.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

This work was supported in part by the National Cancer Center Research and Development Fund (22-38).

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases, 1-3-3 Nakamichi, Higashinari-ku, Osaka, 537-8511, Japan

    Kazuyoshi Motomura

Authors
  1. Kazuyoshi Motomura
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuyoshi Motomura.

About this article

Cite this article

Motomura, K. Sentinel node biopsy for breast cancer: past, present, and future. Breast Cancer 22, 212–220 (2015). https://doi.org/10.1007/s12282-012-0421-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12282-012-0421-7

Keywords

Search

Navigation